Home
/
Nurix Therapeutics, Inc.
/
Financials
/
Quarterly
Nurix Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Nurix Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2024
Feb 29, 2024
$16.59M
Apr 10, 2024
Q3
2023
Aug 31, 2023
$18.47M
Oct 12, 2023
Q2
2023
May 31, 2023
$30.68M
Jul 13, 2023
Q1
2024
Feb 28, 2023
$12.69M
Apr 10, 2024
Q3
2023
Aug 31, 2022
$10.79M
Oct 12, 2023
Q2
2023
May 31, 2022
$11.43M
Jul 13, 2023
Q1
2023
Feb 28, 2022
$9.62M
Apr 13, 2023
Q3
2022
Aug 31, 2021
$10.25M
Oct 6, 2022
Q2
2022
May 31, 2021
$7.09M
Jul 7, 2022
Q1
2022
Feb 28, 2021
$5.01M
Apr 8, 2022
Q3
2021
Aug 31, 2020
$4.09M
Oct 14, 2021
Q2
2021
May 31, 2020
$4.18M
Jul 13, 2021
Q1
2021
Feb 29, 2020
$2.86M
Apr 13, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Feb 28, 2026
$6.25M
Apr 8, 2026
Q3
2025
Aug 31, 2025
$7.89M
Oct 9, 2025
Q2
2025
May 31, 2025
$44.06M
Jul 9, 2025
Q1
2026
Feb 28, 2025
$18.45M
Apr 8, 2026
Q3
2025
Aug 31, 2024
$12.59M
Oct 9, 2025
Q2
2025
May 31, 2024
$12.09M
Jul 9, 2025
Q1
2025
Feb 29, 2024
$16.59M
Apr 8, 2025
Q3
2024
Aug 31, 2023
$18.47M
Oct 11, 2024
Q2
2024
May 31, 2023
$30.68M
Jul 11, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Feb 28, 2026
($87.17M)
Apr 8, 2026
Q3
2025
Aug 31, 2025
($86.42M)
Oct 9, 2025
Q3
2025
May 31, 2025
($43.46M)
Oct 9, 2025
Q2
2025
May 31, 2025
($43.46M)
Jul 9, 2025
Q3
2025
Feb 28, 2025
($56.35M)
Oct 9, 2025
Q1
2026
Feb 28, 2025
($56.35M)
Apr 8, 2026
Q2
2025
Feb 28, 2025
($56.35M)
Jul 9, 2025
Q3
2025
Aug 31, 2024
($48.96M)
Oct 9, 2025
Q3
2025
May 31, 2024
($44.55M)
Oct 9, 2025
Q2
2025
May 31, 2024
($44.55M)
Jul 9, 2025
Q2
2025
Feb 29, 2024
($41.52M)
Jul 9, 2025
Q3
2025
Feb 29, 2024
($41.52M)
Oct 9, 2025
Q1
2025
Feb 29, 2024
($41.52M)
Apr 8, 2025
Q3
2024
Aug 31, 2023
($36.98M)
Oct 11, 2024
Q3
2024
May 31, 2023
($24.28M)
Oct 11, 2024
Q2
2024
May 31, 2023
($24.28M)
Jul 11, 2024
Q3
2024
Feb 28, 2023
($40.73M)
Oct 11, 2024
Q1
2024
Feb 28, 2023
($40.73M)
Apr 10, 2024
Q2
2024
Feb 28, 2023
($40.73M)
Jul 11, 2024
Q3
2023
Aug 31, 2022
($45.71M)
Oct 12, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Feb 28, 2026
($92.50M)
Apr 8, 2026
Q3
2025
Aug 31, 2025
($91.39M)
Oct 9, 2025
Q2
2025
May 31, 2025
($48.32M)
Jul 9, 2025
Q1
2026
Feb 28, 2025
($62.86M)
Apr 8, 2026
Q3
2025
Aug 31, 2024
($54.61M)
Oct 9, 2025
Q2
2025
May 31, 2024
($48.54M)
Jul 9, 2025
Q1
2025
Feb 29, 2024
($45.22M)
Apr 8, 2025
Q3
2024
Aug 31, 2023
($40.01M)
Oct 11, 2024
Q2
2024
May 31, 2023
($26.77M)
Jul 11, 2024
Q1
2024
Feb 28, 2023
($42.95M)
Apr 10, 2024
Q3
2023
Aug 31, 2022
($46.72M)
Oct 12, 2023
Q2
2023
May 31, 2022
($45.72M)
Jul 13, 2023
Q1
2023
Feb 28, 2022
($42.74M)
Apr 13, 2023
Q3
2022
Aug 31, 2021
($29.00M)
Oct 6, 2022
Q2
2022
May 31, 2021
($26.41M)
Jul 7, 2022
Q1
2022
Feb 28, 2021
($24.52M)
Apr 8, 2022
Q3
2021
Aug 31, 2020
($19.19M)
Oct 14, 2021
Q2
2021
May 31, 2020
($13.23M)
Jul 13, 2021
Q1
2021
Feb 29, 2020
($12.55M)
Apr 13, 2021
Q3
2020
Aug 31, 2019
($2.61M)
Oct 14, 2020